Biotech

Biotech narratives get much clearer when the team separates platform ambition from program evidence. The public resources that help most are the ones that connect translational milestones, clinical operations, and regulatory planning instead of letting each discipline pretend it can work alone.

Three signals I would keep in view:
- Biotech strategy gets stronger when teams separate platform promise from program evidence.
- Clinical planning works best when operational realities shape the science plan early.
- Regulatory readiness is easier when evidence packages are built incrementally instead of backwards.

Read first:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.

Documents worth saving:
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NCBI Bookshelf: ncbi.nlm.nih.gov/books/
A deep public archive for primers, reference texts, and method overviews.

Watch next:
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.

If this post is useful, the next contribution should add a real example, a worked document, or a failure case someone else can learn from.